{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"168-664-546-630-894","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"168-664-546-630-894"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8762,"type":"PATENT","title":"Oxford University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8588,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8205,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and Owners = \" Oxford Univ\", \" Univ Oxford\", \"Oxford University\", \"University Oxford\", \"Oxfo* Univ*\", \"Isis\".
Select more for logical variants
Add to collection
Total patents: over 10k
Search applicants and Owners = \" Oxford Univ\", \" Univ Oxford\", \"Oxford University\", \"University Oxford\", \"Oxfo* Univ*\", \"Isis\".
Select more for logical variants
Add to collection
Total patents: over 10k
Wherein H1, H2 and H3 are all helices;\n
L1, L2 and L3 are all loop structures;\n
L2 comprises the sequence CAC or CAXC;\n
L3 comprises the sequence ACXX or AXXX; where X is any nucleotide and where the next nucleotide is G, which forms part of H3; and L1, in the region between H2 and H3, comprises the sequence UUUU; with the proviso that said nucleic acid molecule does not comprise a nucleic acid selected from those listed in Table 1."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid molecule as claimed in claim 1 which is capable of neutralising a virus."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid molecule as claimed in claim 2 which is capable of neutralising HIV-1 virus."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid molecule as claimed in claim 3 which neutralises HIV-1 virus by binding to envelope glycoprotein gp120."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid molecule as claimed in claim 1 which is a truncated aptamer."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid as claimed in claim 1 wherein H1 consists of 4-10 base pairs."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid as claimed in claim 6 comprising the sequence;\nGGGAGACAAGACUAGACGCUCAAUGUGGGCCACGCCCGAUUUUACGCU UUUACCCGCACGCGAUUGGUUUGUUUCCC; CCGACGCUCA AUGUGGGCCA CGCCCGAUUU UACGCUUUUA CCCGCACGCG ACGG; CCGCCGACGC UCAAUGUGGG CCACGCCCGA UUUUACGCUU UUACCCGCAC GCGAUGGCGG; CCGCGCUCAA UGUGGGCCAC GCCCGAUUUU ACGCUUUUAC CCGCACGCGC GG; CCGCUCAAUG UGGGCCACGC CCGAUUUUAC GCUUUUACCC GCACGCGG; CCGCCGCUCA AUGUGGGCCA CGCCCGAUUU UACGCUUUUA CCCGCACGCG GCGG; CCGCCCAACG UGGGCCACGC CCGAUUUUAC GCUUUUACCC GCACGCGG; CCGCGCUCAA UGUGGGCCAC GCCCGAUUUU ACGCUUUUAC CCGCACGCGCGC; CCGCGCUCAA UGUGGGCCAC GCCCGAUUUU ACGCUUUUAC CCGCACGCGC GG; CCGCGCUCAA UGUGGGCCAC GCCCGAUUUU ACGCUUUUAC CCGCACGCGC GG;or CCGCGCUCAA UGUGGGCCAC GCCCGAUUUU ACGCUUUUAC CCGCACGCGC GG. CCGCGCCCAA CGUGGGCCAC GCCCGAUUUU ACGCUUUUAC CCGCACGCGCGG CCGCGCUCAA UGUGGCGCCA CGCGCCGAUU UUACGCUUUU ACCCGCACGCGCGG CCGCGCCCAA CGUGGCGCCA CGCGCCGAUU UUACGCUUUU ACCCGCACGCGCGG CCGCCCAACG CGGGCCACGC CCGAUUUUAC GCAUUUACAC GCACGCGG UCCGCCCAA CGCGGGCCAC GCCCGAUUUU ACGCAUUUAC ACGCACGCGG"],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid molecule as claimed in claim 1 wherein said nucleic acid molecule comprises modified nucleotides."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid molecule as claimed in claim 8, wherein said modified bases are modified by any one or more of the following means:\n
(i) pyrimidine 6 or 8 position, or purine 5 modification with I, Br, Cl, CH3;\n
(ii) pyrimidine 2 position modification with NH3;\n
(iii) pyrimidine modifications O6—CH3, N6—CH3 and N2—CH3;\n
(iv) 2′ sugar modifications;\n
(v) 3′ and/or 5′ capping"],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid complementary to the sequence of claim 1."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["An in vitro method for identifying compounds which block or enhance the interaction between a nucleic acid molecule as claimed in claim 1 and a biological molecule comprising the binding site of said nucleic acid molecules comprising:\n
(a) forming a mixture comprising one or more nucleic acid molecules as defined in claim 1, said biological molecule, and a candidate compound; and optionally\n
(b) incubating the mixture under conditions which, in the absence of the candidate compound, would permit specific binding of the nucleic acid molecule(s) to the biological molecule; and\n
(c) measuring the effect of the candidate compound on the binding of the nucleic acid molecule(s) to the biological molecule."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method as claimed in claim 11, wherein said method utilises microfluidic devices."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A method as claimed in claim 11 wherein said method comprises high throughput screening."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["A method as claimed in claim 11, wherein said method involves competitive inhibition."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["A method as claimed in claim 11, wherein said method uses gp120."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising at least one nucleic acid molecule as claimed in claim 1, optionally together with one or more pharmaceutically acceptable carriers, diluents or excipients."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid molecule as defined in claim 1 for use in the treatment of HIV infection."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The use of a nucleic acid molecule as defined in claim 1 in the manufacture of a medicament for use in the treatment of HIV infection."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of HIV infection comprising administering an effective amount of at least one nucleic acid molecule as defined in claim 1 to a subject in need thereof."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["A nucleic acid molecule having a sequence as shown in table 1."],"number":20,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}